On May 12, 2026, Isomorphic Labs, an AI-first drug design and development company, announced it has raised $2.1 billion in Series B funding. The financing round is led by Thrive Capital, and includes participation from existing backers Alphabet and GV alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, significantly expanding Isomorphic Labs’ global capital base. Wilson Sonsini Goodrich & Rosati advised Isomorphic Labs on the transaction.

Isomorphic Labs was founded with the ambition to leverage the power of AI to reimagine and accelerate drug discovery to bring much-needed treatments to millions of patients globally. The company aims to apply its pioneering AI drug design engine (IsoDDE) to deliver biomedical breakthroughs and is advancing drug design programs across multiple therapeutic areas and drug modalities.

 The Wilson Sonsini team that advised Isomorphic Labs on the transaction includes Allison Spinner, Andrew Gillman, Betty Rosenbaum, Adam Enochs, and Victoria Burch.

 For more information, please see Isomorphic Labs' news release. Additional coverage can be found on Bloomberg and Reuters.